Glial cells – the Strategic Targets in Amyotrophic Lateral Sclerosis Treatment

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F20%3A00539603" target="_blank" >RIV/68378041:_____/20:00539603 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/20:10410822

Result on the web

<a href="https://www.mdpi.com/2077-0383/9/1/261" target="_blank" >https://www.mdpi.com/2077-0383/9/1/261</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jcm9010261" target="_blank" >10.3390/jcm9010261</a>

Result language

angličtina

Original language name

Glial cells – the Strategic Targets in Amyotrophic Lateral Sclerosis Treatment

Original language description

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently by muscle atrophy. To date, numerous gene mutations have been linked to both sporadic and familial ALS, but the effort of many experimental groups to develop a suitable therapy has not, as of yet, proven successful. The original focus was on the degenerating motor neurons, when researchers tried to understand the pathological mechanisms that cause their slow death. However, it was soon discovered that ALS is a complicated and diverse pathology, where not only neurons, but also other cell types, play a crucial role via the so-called non-cell autonomous effect, which strongly deteriorates neuronal conditions. Subsequently, variable glia-based in vitro and in vivo models of ALS were established and used for brand-new experimental and clinical approaches. Such a shift towards glia soon bore its fruit in the form of several clinical studies, which more or less successfully tried to ward the unfavourable prognosis of ALS progression off. In this review, we aimed to summarize current knowledge regarding the involvement of each glial cell type in the progression of ALS, currently available treatments, and to provide an overview of diverse clinical trials covering pharmacological approaches, gene, and cell therapies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/GA19-02046S" target="_blank" >GA19-02046S: Glial cells- the key players in the progression of amyotrophic lateral sclerosis</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Clinical Medicine

ISSN

2077-0383

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

1

Country of publishing house

CH - SWITZERLAND

Number of pages

47

Pages from-to

261

UT code for WoS article

000515388400261

EID of the result in the Scopus database

—